Drug Pipeline Trends in Generics and Biosimilars Impacting Managed Care Strategies

Key Clinical Summary

• Legal, regulatory, and market factors—such as patent litigation, US Food and Drug Administration (FDA) programs, and exclusivity—significantly influence generic drug launch timing and payer strategy.
• Despite FDA approvals, up to 27% of generics remain unlaunched, highlighting delays that impact cost-saving projections.
• High-impact pipeline areas include diabetes, pulmonary disease, oncology, and behavioral health, with substantial opportunities for cost reduction through generics and biosimilars.

An expert panel at the 2026 Academy of Managed Care Pharmacy (AMCP) conference provided new insights into the evolving drug pipeline and revealed that regulatory, legal, and market dynamics continue to delay generic entry and shape biosimilar adoption, with significant implications for payer decision-making.

Drug Pipeline, Regulatory Pathways, and Market Dynamics

Andrew Levitsky, PharmD, BCPS, outlined key regulatory and legal factors affecting generic drug launches, including patent thickets, settlement agreements, and “launch at risk” strategies. He also highlighted the growing importance of FDA programs such as accelerated approval and priority review vouchers, which can shorten development timelines for high-need therapies.

A notable legal development involves skinny labeling, where generics exclude patented indications. Litigation such as GSK v Teva has introduced uncertainty, potentially delaying generic entry and affecting payer cost strategies.

Dr Levitsky emphasized that while approximately 70 branded drugs face potential loss of exclusivity, only a subset will result in timely generic competition. Importantly, about 27% of approved generics remain unlaunched, with an average of 200 delayed beyond 2 years post-approval.

High-impact therapeutic categories include the following:

• Type 2 diabetes: Significant savings potential with SGLT2 and DPP-4 inhibitor generics
• Pulmonary diseases: Agents like nintedanib and selexipag with multibillion-dollar market impact
• Oncology/hematology: Pomalidomide showing early generic price reductions to ~40% of brand
• Behavioral health: Vortioxetine and brivaracetam expected to expand access through generic entry

Generic pricing trends depend heavily on competition. Initial prices may remain close to brand with limited entrants but decline significantly over time due to price erosion.

Payer Strategy and Emerging Therapies

According to Marina Sehman, PharmD, CSP, biosimilars and specialty pipeline agents present both opportunities and challenges for payers. While biosimilars can generate substantial savings, adoption varies widely by therapeutic area, with faster uptake in oncology and slower penetration in immunology and ophthalmology.

Dr Sehman noted that only about 10% of biologics are expected to face biosimilar competition in the next decade, limiting near-term cost relief.

Emerging therapies—including novel agents for essential tremor, attention-deficit/hyperactivity disorder (ADHD), diabetes, and psychiatric conditions—may carry high annual costs (ranging from ~$5000 to over $50 000), reinforcing the need for utilization management strategies such as step therapy.

She also highlighted growing interest in innovative modalities, including psychedelic-assisted therapies, which may introduce complex regulatory and reimbursement considerations.

Managed Care and Cost Containment

For payers and managed care organizations, the session underscores the importance of distinguishing between FDA approval and actual market entry when forecasting savings. Strategic formulary management should account for delayed generic launches, competitive dynamics, and biosimilar uptake variability.

Incorporating step therapy, monitoring pipeline developments, and evaluating pricing trends will be essential to optimize cost containment while maintaining patient access.

Future Outlook for Generics, Biosimilars, and Pipeline Innovation

The evolving drug pipeline presents both opportunities and uncertainties for health care stakeholders. While generics and biosimilars remain key drivers of cost savings, legal, regulatory, and market barriers continue to shape their real-world impact. Ongoing monitoring of pipeline trends and policy developments will be critical for informed decision-making.

Reference

Levitsky A, Sehman M. Drug Pipeline: Traditional Pharmaceuticals (Brands and Generics) and Biosimilars. Presented at: AMCP 2026; April 13-15; Nashville, TN.